Dionysis Nikolopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7130704/publications.pdf

Version: 2024-02-01

933447 888059 17 404 10 17 citations h-index g-index papers 17 17 17 487 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Annals of the Rheumatic Diseases, 2020, 79, 232-241.	0.9	71
2	Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. Current Vascular Pharmacology, 2020, 18, 549-565.	1.7	61
3	Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 758-766.	0.9	50
4	Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 242-253.	0.9	44
5	Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. Mediterranean Journal of Rheumatology, 2019, 30, 7-15.	0.8	33
6	Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the  Attikon' cohort. Lupus, 2020, 29, 514-522.	1.6	31
7	Update on the pathogenesis of central nervous system lupus. Current Opinion in Rheumatology, 2019, 31, 669-677.	4.3	22
8	Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. Lupus Science and Medicine, 2020, 7, e000394.	2.7	18
9	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. Seminars in Arthritis and Rheumatism, 2020, 50, 1387-1393.	3.4	16
10	Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. Expert Review of Clinical Immunology, 2021, 17, 317-329.	3.0	10
11	The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Clinical Rheumatology, 2021, 40, 1447-1456.	2.2	9
12	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. Annals of the Rheumatic Diseases, 2021, 80, 1175-1182.	0.9	9
13	Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the "Attikon―Lupus Cohort. Frontiers in Neurology, 2022, 13, .	2.4	8
14	Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort. Rheumatology, 2021, 60, 4166-4174.	1.9	6
15	First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist. American Journal of Medicine, 2022, 135, 244-253.e3.	1.5	6
16	Suspected systemic rheumatic diseases in patients presenting with cytopenias. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101425.	3.3	5
17	Tailored treatment strategies and future directions in systemic lupus erythematosus. Rheumatology International, 2022, 42, 1307-1319.	3.0	5